BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6136
- TODAY'S CHANGE (%)-0.0014 (-0.2276%)
- Bid / Lots0.6050/ 1
- Ask / Lots0.7000/ 9
- Open / Previous Close0.6100 / 0.6150
- Day Range
- 52 Week Range
- Volume113,661
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 3218 | 0.61 |
| 09:34 ET | 150 | 0.6397 |
| 09:39 ET | 700 | 0.62035 |
| 09:48 ET | 2690 | 0.62 |
| 09:57 ET | 100 | 0.6298 |
| 09:59 ET | 100 | 0.62 |
| 10:03 ET | 10900 | 0.6299 |
| 10:15 ET | 5000 | 0.62 |
| 10:19 ET | 4200 | 0.62 |
| 10:21 ET | 8998 | 0.62 |
| 10:26 ET | 100 | 0.62 |
| 10:28 ET | 200 | 0.619 |
| 10:32 ET | 11841 | 0.608 |
| 10:42 ET | 4979 | 0.6073 |
| 10:53 ET | 400 | 0.6051 |
| 10:55 ET | 600 | 0.6073 |
| 11:02 ET | 300 | 0.6073 |
| 11:04 ET | 114 | 0.6073 |
| 11:11 ET | 100 | 0.6073 |
| 11:18 ET | 200 | 0.6175 |
| 11:20 ET | 100 | 0.629 |
| 11:29 ET | 200 | 0.6299 |
| 11:56 ET | 124 | 0.6175 |
| 12:07 ET | 900 | 0.6172 |
| 12:09 ET | 900 | 0.6199 |
| 12:18 ET | 2000 | 0.6199 |
| 12:27 ET | 1000 | 0.62 |
| 12:32 ET | 500 | 0.605 |
| 12:36 ET | 100 | 0.61 |
| 12:43 ET | 1000 | 0.618365 |
| 12:48 ET | 211 | 0.6101 |
| 12:50 ET | 200 | 0.61 |
| 12:56 ET | 3200 | 0.61 |
| 12:59 ET | 500 | 0.617098 |
| 01:08 ET | 1000 | 0.6184 |
| 01:10 ET | 281 | 0.6101 |
| 01:12 ET | 330 | 0.6183 |
| 01:14 ET | 300 | 0.6157 |
| 01:15 ET | 500 | 0.6142 |
| 01:17 ET | 500 | 0.61 |
| 01:19 ET | 234 | 0.61 |
| 01:44 ET | 100 | 0.615395 |
| 01:46 ET | 4999 | 0.610101 |
| 01:48 ET | 100 | 0.6184 |
| 01:53 ET | 150 | 0.6183 |
| 02:02 ET | 100 | 0.618 |
| 02:06 ET | 223 | 0.6183 |
| 02:31 ET | 800 | 0.61 |
| 02:38 ET | 9500 | 0.6111 |
| 02:44 ET | 100 | 0.61 |
| 02:49 ET | 100 | 0.61 |
| 02:56 ET | 4945 | 0.6183 |
| 03:00 ET | 415 | 0.61 |
| 03:09 ET | 140 | 0.61415 |
| 03:14 ET | 3068 | 0.6183 |
| 03:18 ET | 211 | 0.61415 |
| 03:20 ET | 620 | 0.6142 |
| 03:21 ET | 403 | 0.6183 |
| 03:23 ET | 150 | 0.6101 |
| 03:25 ET | 2332 | 0.618 |
| 03:27 ET | 425 | 0.6184 |
| 03:32 ET | 643 | 0.61 |
| 03:43 ET | 962 | 0.61415 |
| 03:48 ET | 100 | 0.61 |
| 03:54 ET | 213 | 0.61415 |
| 03:56 ET | 1000 | 0.61415 |
| 03:59 ET | 9989 | 0.6136 |
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
Aug 15, 2024
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Thursday Aug 15, 2024 by Dow Jones
7:00AM ET on Thursday Aug 15, 2024 by Dow JonesPress Release: BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Thursday Aug 15, 2024 by Dow Jones
7:00AM ET on Thursday Aug 15, 2024 by Dow Jones
Aug 8, 2024
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024, from 7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 54.8M | -0.8x | --- |
SS Innovations International Inc | 54.6M | -2.3x | --- |
Kronos Bio Inc | 59.4M | -0.6x | --- |
Omega Therapeutics Inc | 67.3M | -0.9x | --- |
LAVA Therapeutics NV | 42.1M | -1.8x | --- |
Atara Biotherapeutics Inc | 53.6M | -0.2x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.8M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
